The global in vitro diagnostics market size was estimated at USD 108.30 billion in 2024 and is projected to reach USD 150.13 billion by 2030, growing at a CAGR of 5.62% from 2025 to 2030. This growth is largely driven by the rising worldwide demand for diagnostic solutions that are accurate, fast, and tailored to individual patients.

Several key factors contribute to this market expansion, including the growing incidence of chronic and infectious diseases and continual advancements in diagnostic technology. There is a notable shift toward value-based healthcare models that emphasize early detection and preventive care, which further fuels demand for innovative diagnostic methods. The adoption of digital health technologies, artificial intelligence (AI), and data analytics within diagnostic platforms is improving test precision and aiding clinical decision-making. Additionally, the increasing use of point-of-care testing, the rise of personalized medicine, and growth in emerging markets, combined with a heightened focus on pandemic preparedness, are creating substantial growth opportunities for industry participants.

The rising prevalence of chronic diseases, infectious illnesses, and genetic disorders such as Alzheimer’s disease, Turner syndrome, and Parkinson’s disease is expected to further drive demand for in vitro diagnostic tools during the forecast period. For example, according to the U.S. Centers for Disease Control and Prevention (CDC), chronic conditions like cancer, diabetes, chronic kidney disease, and respiratory diseases such as asthma are responsible for seven out of ten deaths annually in the United States. Furthermore, approximately six out of ten American adults are likely to live with a chronic disease, which collectively incurs an estimated USD 4.1 trillion in annual healthcare costs in the country. In 2024, around 620,000 cases and 213 deaths related to infectious diseases were reported, predominantly in the Americas, with Brazil, Paraguay, and Argentina experiencing the highest burdens. Significant case numbers were also recorded in Asia, especially in India and Pakistan, while Senegal was the only African country affected. Europe reported one locally acquired case in France and 118 cases in La Réunion, indicating the global spread and ongoing impact of these diseases on healthcare systems.

Key Market Trends & Insights:

• In 2024, North America led the global in vitro diagnostics (IVD) industry, capturing a dominant share of 47.43% of the market. This strong position highlights the region's advanced healthcare infrastructure, widespread adoption of innovative diagnostic technologies, and significant investments in research and development.

• Meanwhile, the Asia Pacific region is emerging as the fastest-growing market within the in vitro diagnostics sector, with an expected compound annual growth rate (CAGR) of 6.57% during the forecast period. This rapid growth is driven by increasing healthcare expenditure, expanding healthcare access, rising prevalence of chronic and infectious diseases, and growing awareness about early diagnosis and personalized medicine in the region.

• When analyzing the market by product type, the reagents segment accounted for the largest portion, holding a substantial 65.54% share of the global in vitro diagnostics market in 2024. Reagents are essential components used in various diagnostic tests, and their dominance reflects ongoing demand for testing materials across numerous healthcare applications.

• In terms of technology, the immunoassay segment generated the largest revenue share within the in vitro diagnostics market in 2024. Immunoassays are widely used for detecting and quantifying specific proteins or molecules and are integral in diagnosing infectious diseases, hormonal imbalances, and other conditions, which explains their significant market presence.

• Regarding application areas, the infectious diseases segment dominated the in vitro diagnostics industry in 2024. This leadership is attributed to the continuous global need for effective detection, monitoring, and management of infectious diseases, which remain a critical public health concern worldwide.

Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 108.30 Billion

• 2030 Projected Market Size: USD 150.13 Billion

• CAGR (2025-2030): 5.62%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Some of the leading companies operating in the in vitro diagnostics (IVD) market include Abbott, bioMérieux, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific, Inc., and Bio-Rad Laboratories, Inc. These well-established players invest significantly in cutting-edge technologies and robust infrastructure, enabling them to efficiently process and analyze large volumes of diagnostic data. To maintain and strengthen their market position, these companies actively pursue strategies such as launching new products, engaging in mergers and acquisitions, and forming strategic partnerships. These approaches help them expand their product portfolios, introduce advanced and innovative diagnostic solutions, and enhance their overall market competitiveness.

On the other hand, emerging companies like ARUP Laboratories, RayBiotech, Inc., Randox Laboratories Ltd., Everlywell, Orreco, and Biostarks are also making notable strides in the in vitro diagnostics industry. These newer entrants focus strongly on differentiating their products to penetrate the market effectively. They are actively developing novel, precise IVD testing products aimed at improving health service quality. Additionally, many of these emerging players collaborate with research institutions, government agencies, and established global leaders to broaden their product offerings and tap into potential markets, thereby accelerating their growth and impact within the industry.

Key Players

• Abbott

• Bio-Rad Laboratories, Inc

• Siemens Healthineers AG

• BIOMÉRIEUX

• BD

• QIAGEN

• Quidel Corporation

• F. Hoffmann-La Roche Ltd.

• Danaher

• Quest Diagnostics Incorporated

• Agilent Technologies, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The in vitro diagnostics market is experiencing steady growth driven by increasing demand for accurate and rapid diagnostic solutions, advancements in technology, and a focus on early disease detection and personalized healthcare. Key factors include rising prevalence of chronic and infectious diseases, integration of AI and digital health, and expansion in emerging markets. Established players continue to innovate and expand through strategic initiatives, while emerging companies focus on product differentiation and collaborations to capture market opportunities.